Apollo Endosurgery to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

Rhea-AI Summary

Apollo Endosurgery (NASDAQ: APEN) will release its financial results for Q4 and the full year ended December 31, 2020 on February 25, 2021, after market close. A conference call will be held at 3:30 p.m. CT to discuss these results. Apollo specializes in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, with products available in over 75 countries. Risks related to the ongoing COVID-19 pandemic may impact demand and operations. For more information, visit www.apolloendo.com.

Positive

• None.

Negative

• Uncertainty about the ongoing impact of the COVID-19 pandemic on operations and product demand.
• Potential risks regarding liquidity and global supply chains.

AUSTIN, TX / ACCESSWIRE / February 22, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 after the market closes. In conjunction with the release, Apollo will host a conference call at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. To join the call by telephone, please dial +1-973-528-0011. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.apolloendo.com.

A replay of the webcast will be made available on Apollo's website, www.apolloendo.com, shortly after completion of the call.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on next-generation, minimally invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, the ORBERA^® Intragastric Balloon, and the X-Tack™ Endoscopic HeliX Tacking System.

Apollo's common stock is traded on NASDAQ Global Market under the symbol "APEN". For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.

Cautionary Note on Forward-Looking Statements

Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. In addition, there is uncertainty about the continued spread of the COVID-19 virus and the impact it may have on the Company's operations, the demand for the Company's products, the Company's liquidity position, global supply chains and economic activity in general. Important factors that could cause actual results to differ materially include: the advancement of Apollo products; development of enhancements to Apollo's existing products and technologies; market acceptance of Apollo's products; the execution of Apollo's gross margin improvement projects; the ability to collect future payments from ReShape; statements relating to the availability of cash for Apollo's future operations; and Apollo's ability to support the adoption of its products and broaden its product portfolio as well as other factors detailed in Apollo's periodic reports filed with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2019 and its Form 10-Q for the period ending September 30, 2020. Copies of reports filed with the SEC are posted on Apollo's website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Disclosure Information

Apollo uses the investor relations section of its website as a means of complying with its disclosure obligations under Regulation FD. Accordingly, we recommend that investors should monitor Apollo's investor relations website in addition to following Apollo's press releases, SEC filings, and public conference calls and webcasts.

Contact:

Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
investor-relations@apolloendo.com

Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
mkreps@darrowir.com

SOURCE: Apollo Endosurgery, Inc.

View source version on accesswire.com:
https://www.accesswire.com/631178/Apollo-Endosurgery-to-Report-Fourth-Quarter-and-Full-Year-2020-Financial-Results-on-February-25-2021

FAQ

When will Apollo Endosurgery report its Q4 2020 financial results?

Apollo Endosurgery will report its Q4 2020 financial results on February 25, 2021.

What time is the Apollo Endosurgery conference call scheduled?

The conference call is scheduled for 3:30 p.m. CT on February 25, 2021.

Where can I find Apollo Endosurgery's financial results?

Financial results will be available on Apollo's investor relations website at www.apolloendo.com.

What risks may affect Apollo Endosurgery's business in 2021?

Risks include the ongoing COVID-19 pandemic's impact on operations, product demand, and liquidity.

In how many countries are Apollo Endosurgery's products available?

Apollo Endosurgery's products are offered in over 75 countries.